Logo image of ALIM

ALIMERA SCIENCES INC (ALIM) Stock Fundamental Analysis

NASDAQ:ALIM - Nasdaq - US0162592028 - Common Stock - Currency: USD

5.54  -0.01 (-0.18%)

After market: 5.54 0 (0%)

Fundamental Rating

4

Taking everything into account, ALIM scores 4 out of 10 in our fundamental rating. ALIM was compared to 197 industry peers in the Pharmaceuticals industry. ALIM has a bad profitability rating. Also its financial health evaluation is rather negative. ALIM is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

ALIM had negative earnings in the past year.
In the past year ALIM has reported a negative cash flow from operations.
ALIM had negative earnings in each of the past 5 years.
In the past 5 years ALIM always reported negative operating cash flow.
ALIM Yearly Net Income VS EBIT VS OCF VS FCFALIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M

1.2 Ratios

ALIM has a better Return On Assets (-10.16%) than 72.82% of its industry peers.
The Return On Equity of ALIM (-39.38%) is better than 62.05% of its industry peers.
With a decent Return On Invested Capital value of 0.12%, ALIM is doing good in the industry, outperforming 76.92% of the companies in the same industry.
Industry RankSector Rank
ROA -10.16%
ROE -39.38%
ROIC 0.12%
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALIM Yearly ROA, ROE, ROICALIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

Looking at the Operating Margin, with a value of 0.20%, ALIM is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
ALIM's Gross Margin of 86.39% is amongst the best of the industry. ALIM outperforms 90.26% of its industry peers.
In the last couple of years the Gross Margin of ALIM has remained more or less at the same level.
Industry RankSector Rank
OM 0.2%
PM (TTM) N/A
GM 86.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
ALIM Yearly Profit, Operating, Gross MarginsALIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALIM is destroying value.
The number of shares outstanding for ALIM has been increased compared to 1 year ago.
Compared to 5 years ago, ALIM has more shares outstanding
ALIM has a better debt/assets ratio than last year.
ALIM Yearly Shares OutstandingALIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ALIM Yearly Total Debt VS Total AssetsALIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -1.37, we must say that ALIM is in the distress zone and has some risk of bankruptcy.
ALIM has a Altman-Z score (-1.37) which is in line with its industry peers.
A Debt/Equity ratio of 1.80 is on the high side and indicates that ALIM has dependencies on debt financing.
The Debt to Equity ratio of ALIM (1.80) is worse than 78.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Altman-Z -1.37
ROIC/WACC0.01
WACC9.95%
ALIM Yearly LT Debt VS Equity VS FCFALIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

ALIM has a Current Ratio of 2.79. This indicates that ALIM is financially healthy and has no problem in meeting its short term obligations.
ALIM has a Current ratio of 2.79. This is comparable to the rest of the industry: ALIM outperforms 45.13% of its industry peers.
A Quick Ratio of 2.62 indicates that ALIM has no problem at all paying its short term obligations.
ALIM has a Quick ratio (2.62) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.62
ALIM Yearly Current Assets VS Current LiabilitesALIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.66% over the past year.
The Revenue has grown by 69.76% in the past year. This is a very strong growth!
The Revenue has been growing by 11.62% on average over the past years. This is quite good.
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%

3.2 Future

Based on estimates for the next years, ALIM will show a very strong growth in Earnings Per Share. The EPS will grow by 22.30% on average per year.
ALIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.81% yearly.
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALIM Yearly Revenue VS EstimatesALIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
ALIM Yearly EPS VS EstimatesALIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

3

4. Valuation

4.1 Price/Earnings Ratio

ALIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 28.59, the valuation of ALIM can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALIM indicates a somewhat cheap valuation: ALIM is cheaper than 77.44% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.77, ALIM is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 28.59
ALIM Price Earnings VS Forward Price EarningsALIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

ALIM's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ALIM is cheaper than 77.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.66
ALIM Per share dataALIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALIM's earnings are expected to grow with 30.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.56%
EPS Next 3Y30.12%

0

5. Dividend

5.1 Amount

No dividends for ALIM!.
Industry RankSector Rank
Dividend Yield N/A

ALIMERA SCIENCES INC

NASDAQ:ALIM (9/13/2024, 8:00:00 PM)

After market: 5.54 0 (0%)

5.54

-0.01 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2024-08-06/bmo
Earnings (Next)10-24 2024-10-24/amc
Inst Owners0.2%
Inst Owner Change0%
Ins Owners30.17%
Ins Owner Change0%
Market Cap301.27M
Analysts48.89
Price Target5.78 (4.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.01%
Min EPS beat(2)-107.6%
Max EPS beat(2)-60.41%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.13%
Min Revenue beat(2)1.39%
Max Revenue beat(2)2.87%
Revenue beat(4)4
Avg Revenue beat(4)2.76%
Min Revenue beat(4)0.83%
Max Revenue beat(4)5.96%
Revenue beat(8)5
Avg Revenue beat(8)-1.87%
Revenue beat(12)7
Avg Revenue beat(12)-1.43%
Revenue beat(16)10
Avg Revenue beat(16)1.21%
PT rev (1m)0%
PT rev (3m)-29.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 28.59
P/S 3.02
P/FCF N/A
P/OCF N/A
P/B 7.77
P/tB N/A
EV/EBITDA 28.66
EPS(TTM)-0.31
EYN/A
EPS(NY)0.19
Fwd EY3.5%
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.83
BVpS0.71
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.16%
ROE -39.38%
ROCE 0.15%
ROIC 0.12%
ROICexc 0.13%
ROICexgc 0.56%
OM 0.2%
PM (TTM) N/A
GM 86.39%
FCFM N/A
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
F-Score4
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Debt/EBITDA 5.55
Cap/Depr 1.81%
Cap/Sales 0.22%
Interest Coverage 0.03
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.62
Altman-Z -1.37
F-Score4
WACC9.95%
ROIC/WACC0.01
Cap/Depr(3y)299.05%
Cap/Depr(5y)185.34%
Cap/Sales(3y)31.69%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%
EBIT growth 1Y101.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3584.36%
EBIT Next 3Y329.62%
EBIT Next 5Y187.7%
FCF growth 1Y62.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3YN/A
OCF growth 5YN/A